PRECEDE BIOSCIENCES
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition.
PRECEDE BIOSCIENCES
Industry:
Biopharma Biotechnology Health Care
Founded:
2005-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.precede.bio
Total Employee:
11+
Status:
Active
Contact:
(617) 356-1457
Email Addresses:
[email protected]
Total Funding:
57 M USD
Technology used in webpage:
Organization Schema CrUX Dataset CrUX Top 50m
Current Employees Featured
Founder
Investors List
Illumina Ventures
Illumina Ventures investment in Series A - Precede Biosciences
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Precede Biosciences
Bristol-Myers Squibb
Bristol-Myers Squibb investment in Series A - Precede Biosciences
Lilly Asia Ventures
Lilly Asia Ventures investment in Series A - Precede Biosciences
Qatar Investment Authority
Qatar Investment Authority investment in Series A - Precede Biosciences
Binney Street Capital
Binney Street Capital investment in Series A - Precede Biosciences
5AM Ventures
5AM Ventures investment in Series A - Precede Biosciences
Official Site Inspections
http://www.precede.bio Semrush global rank: 6.45 M Semrush visits lastest month: 1.08 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Precede Biosciences"
Precede Biosciences - Crunchbase Company Profile
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to …See details»
Precede 2025 Company Profile: Valuation, Funding & Investors
Www.precede.bio. Formerly Known As. Nuscan Diagnostics. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 1 Design Center Place; …See details»
Precede Biosciences Emerges from Stealth to Dramatically Impact ...
Oct 5, 2023 Precede seeks to improve success rates in drug development and to be a part of building a future where every patient can receive a rapid, minimally invasive diagnosis and …See details»
Precede Biosciences - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Oct 5, 2023: Series A - …See details»
Company Spotlight – Precede Bio - Illumina Ventures
Together, they developed a comprehensive epigenomic platform that could be deployed as a simple blood test. Later, they joined forces with Rehan Verjee, a biopharmaceutical executive, …See details»
Precede Biosciences Company Profile: Financials, Valuation, and …
Precede Biosciences is a privately-held company providing a blood-based approach to revealing disease-defining transcriptional biology. Precede Biosciences was founded in 2021 by …See details»
Precede Biosciences Emerges from Stealth to Dramatically Impact ...
Oct 5, 2023 Precede has $57M in backing from renowned venture and private equity investors. BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences emerges from stealth …See details»
Precede Biosciences - VentureRadar
Precede Biosciences is revolutionizing precision medicine by utilizing a cutting-edge platform that reveals critical disease-defining transcriptional biology from a simple blood test. Their …See details»
Q&A with Rehan Verjee, Co-Founder and CEO of …
What key considerations are helping Precede Bio bolster its position in the liquid biopsy space competitively? The most important one to emphasize is strategic clarity. The team and I are very focused on expanding the reach of precision …See details»
Precede Biosciences - Updates, News, Events, Signals & Triggers
Precede Biosciences presented scientific data for its epigenomic liquid biopsy platform at AACR 2024, showcasing its potential in precision medicine. The company also announced positive …See details»
Precede Biosciences Launches with Cell-Free Genomic Diagnostic …
Oct 5, 2023 Precede’s platform uses advanced and unique molecular biology and machine learning to create profiles of circulating chromatin and the DNA methylome. This gives users …See details»
Precede Biosciences Emerges from Stealth to Dramatically
Oct 5, 2023 Precede aims to accelerate the development and use of precision medicines by providing unprecedented resolution into disease-defining biology at scale Precede has $57M …See details»
Precede Biosciences Emerges from Stealth to Dramatically
Oct 5, 2023 Precede has $57M in backing from renowned venture and private equity investors BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Precede Biosciences emerges from stealth …See details»
Precede Biosciences, Inc. - Scientist.com
Precede Biosciences, Inc. Start a request. Favorite Year Established: 2021 Website: precede.bio: Headquarters: Boston, MA, US Company Type: New Startup (0-1M TTM Revenue) …See details»
Precede Biosciences - Work in biotech
Precede Biosciences has developed a first-in-class liquid biopsy platform to provide insights into disease-defining biology. Precede's platform uses machine learning and molecular biology to …See details»
Precede Biosciences Presents a Novel ER Transcriptional …
Boston, MA – December 12 2024 – Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy …See details»
Precede Biosciences Unveils Groundbreaking Clinical Data for its ...
Boston, MA – October 21, 2023 – Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced the …See details»
Precede Biosciences Announces First Scientific Data from its Liquid ...
Boston, MA – October 15, 2023 – Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, advances its mission …See details»
Precede Biosciences to Present Scientific Data For Its …
Boston, MA – March 5, 2024 – Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, today announced three …See details»